CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed
Drug / intervention
Sorbinildrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00000159
NCT00000159Phase 3Completed
CompareCT.gov

Sorbinil Retinopathy Trial (SRT)

National Eye Institute (NEI)·interventional·Posted Sep 24, 1999·Updated Jun 24, 2005

In Brief

A Phase 3 clinical trial evaluating Sorbinil for Diabetic Retinopathy and Diabetes Mellitus. Completed.

Detailed Summary

To evaluate the safety and efficacy of the investigational drug sorbinil, an aldose reductase inhibitor, in preventing the development of diabetic retinopathy and neuropathy in persons with insulin-dependent diabetes.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetic Retinopathy, Diabetes Mellitus
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
198319841985198619871988198919901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 24, 1999
Enrollment StartAug 1, 1983
TodayJul 2, 2026
Posted 26.8 years ago

Interventions

Sorbinildrug